19 active not recruiting. 19 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Active not recruiting 19 |
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression Treatment with Ketamine Hydrochloride Prolonged-Release Tablets - Major Depressive Disorder (MDD) | Phase 2 | Active not recruiting | Daniel Lindqvist | 12 | 2026-03-13 | 2026-06-18 |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults ABX-002 - Bipolar Disorder Depression | Phase 2 | Active not recruiting | Autobahn Therapeutics, Inc. | 35 | 2025-03-28 | 2026-05-26 |
| Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression Omega 3, Placebo - Treatment Resistant Depression, Inflammation | Phase 2 | Active not recruiting | Massachusetts General Hospital | 14 | 2025-01-30 | 2026-07-01 |
| Mindfulness Engaged Neurostimulation for Depression Medi-TBS - Depression, Treatment Resistant Depression | Phase 2 | Active not recruiting | University of California, San Diego | 70 | 2024-05-15 | 2026-03-31 |
| Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin - Major Depressive Disorder, Depression | Phase 2 | Active not recruiting | University Health Network, Toronto | 92 | 2024-02-05 | 2026-07-09 |
| i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride - Major Depressive Disorder, Suicide | Phase 2 | Active not recruiting | University Health Network, Toronto | 76 | 2024-01-02 | 2026-10-06 |
| Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer Psilocybin, Placebo - Cancer, Major Depressive Disorder | Phase 2 | Active not recruiting | Sunstone Medical | 56 | 2023-10-23 | 2026-05-06 |
| Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders Dasatinib, quercetin - Schizophrenia, Treatment Resistant Depression | Phase 2 | Active not recruiting | Washington University School of Medicine | 40 | 2023-07-01 | 2026-04-21 |
| Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women MWSH plus Candlelit Care, MWSH - Pregnancy Related, Pregnancy Complications | Phase 2 / Phase 3 | Active not recruiting | Cedars-Sinai Medical Center | 150 | 2023-06-01 | 2026-10-22 |
| D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT) D-Cycloserine, Intermittent Theta Burst Stimulation - Major Depressive Disorder | Phase 2 | Active not recruiting | The Alfred | 180 | 2023-04-21 | 2025-12-04 |
| A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder Psilocybin - Major Depressive Disorder | Phase 2 | Active not recruiting | COMPASS Pathways | 102 | 2023-01-30 | 2025-08-19 |
| ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression ELE-101, ELE-101 Placebo - Healthy Volunteers, Major Depressive Disorder | Phase 1 / Phase 2 | Active not recruiting | Eleusis Therapeutics | 84 | 2022-10-27 | 2025-02-19 |
| Neurocognitive Effects of FMT in MDD Patients With and Without IBS Fecal Microbiota Transplantation - Major Depressive Disorder, Irritable Bowel Syndrome | Phase 2 / Phase 3 | Active not recruiting | Valerie Taylor | 133 | 2022-04-06 | 2026-03-19 |
| Psilocybin Therapy for Depression in Bipolar II Disorder Psilocybin therapy - Bipolar II Disorder | Phase 2 | Active not recruiting | University of California, San Francisco | 14 | 2022-01-28 | 2024-09-25 |
| Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder Psilocybin, Placebo - Major Depressive Disorder, Alcohol Use Disorder | Phase 2 | Active not recruiting | Johns Hopkins University | 90 | 2021-04-14 | 2026-03-13 |
| Combination of Novel Therapies for CKD Comorbid Depression Bupropion, Behavioral activation therapy, Placebo - Chronic Kidney Diseases, Major Depressive Disorder | Phase 2 | Active not recruiting | Stony Brook University | 201 | 2020-09-24 | 2026-08-11 |
| Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression Probiotic Supplement, Inert Compound - Bipolar Depression | Phase 2 | Active not recruiting | Sheppard Pratt Health System | 80 | 2018-12-11 | 2026-04-07 |
| CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery) Epidural delivery system, Entonox, Meperidine - Depression, Postpartum, Analgesia, Obstetrical | Phase 2 / Phase 3 | Active not recruiting | KK Women's and Children's Hospital | 881 | 2017-06-15 | 2026-08-06 |
| Smoking Cessation for Depressed Smokers Smoking Cessation Treatment, Nicotine Replacement Therapy, CBASP - Smoking, Depression | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 91 | 2007-06-28 | 2026-06-15 |
Depressive Disorder, Major (13) · Depression (7) · Depressive Disorder, Treatment-Resistant (5) · Bipolar Disorder (3) · Depression, Postpartum (2) · Inflammation (2) · Aging, Premature (1) · Agnosia (1) · Alcoholism (1) · Anxiety Disorders (1) · Depressive Disorder (1) · Irritable Bowel Syndrome (1) · Kidney Failure, Chronic (1) · Mental Disorders (1)
Mental Disorders (18) · Depressive Disorder (15) · Behavior (8) · Behavioral Symptoms (8) · Pathological Conditions, Signs and Symptoms (5) · Bipolar and Related Disorders (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Pathologic Processes (3) · Signs and Symptoms (3) · Urogenital Diseases (3) · Puerperal Disorders (2) · Alcohol-Related Disorders (1) · Body Weight (1) · Chemically-Induced Disorders (1)
Psilocybin (3) · Bupropion (1) · Cycloserine (1) · Dasatinib (1) · Docosahexaenoic Acids (1) · Entonox (1) · Fecal Microbiota Transplantation (1) · Fentanyl (1) · Ketamine (1) · Meperidine (1) · Midazolam (1) · Nicotine Replacement Therapy (1) · Nitrous Oxide (1) · Quercetin (1) · Remifentanil (1)
University Health Network, Toronto (2) · Autobahn Therapeutics, Inc. (1) · COMPASS Pathways (1) · Cedars-Sinai Medical Center (1) · Daniel Lindqvist (1) · Eleusis Therapeutics (1) · Johns Hopkins University (1) · KK Women's and Children's Hospital (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Sheppard Pratt Health System (1) · Stony Brook University (1) · Sunstone Medical (1) · The Alfred (1) · University of California, San Diego (1)
United States (12) · Canada (3) · Australia (1) · Singapore (1) · Sweden (1) · United Kingdom (1)
Ban Leong Sng, FANZCA (1) · Bridgette Franey, MD (1) · Daniel Lindqvist, PhD, MD (1) · David Guard, PhD (1) · Eric Lenze, MD (1) · Faith Dickerson, PhD, MPH (1) · Frederick S Barrett, PhD (1) · Jan Blalock, PhD (1) · Joshua D Woolley, MD,PhD (1) · Joshua Rosenblat, MD, MSc (1) · Jyoti Mishra, PhD (1) · Leo Chen, MBBS PhD FRANZCP (1) · Mark H Rapaport, MD (1) · Neel Bhatt (1) · Rodrigo Mansur (1)
PMID 37491196, PMID 37990597, PMID 39732915, PMID 40113655, PMID 40375477, PMID 40443429, PMID 42049811, PMID 42092800, PMID 42314868, PMID 42765891
2025 (1), R01DK124379 (1), R01MH076776 (1), R01MH087692 (1), R21MD017396 (1)